Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Olmutinib

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Olmutinib (Olita™) is an orally bioavailable third generation epidermal growth factor receptor tyrosine kinase inhibitor… Expand
Is this relevant?
Review
2019
Review
2019
OBJECTIVES The aim of this phase 1/2 study was to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of… Expand
Is this relevant?
2019
2019
The main objective of this phase I trial was to investigate pharmacokinetics (PK) of olmutinib in three racial subjects. We also… Expand
Is this relevant?
2019
2019
Olmutinib (HM61713) is a third-generation tyrosine kinase inhibitor active against mutant EGFR, including T790M in nonsmall cell… Expand
  • figure 2
  • figure 1
Is this relevant?
2018
2018
Overexpressing of ATP-binding cassette (ABC) transporters is the essential cause of multidrug resistance (MDR), which is a… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2018
2018
The main characteristic of tumor cell resistance is multidrug resistance (MDR). MDR is the principle cause of the decline in… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
2018
2018
olmutinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for the treatment of non… Expand
Is this relevant?
2018
2018
Drug induced lichen planus like eruption is an uncommon cutaneous adverse effect of several drugs. This appears symmetric… Expand
  • figure 1
  • figure 2
Is this relevant?
2016
2016
Olmutinib (OlitaTM) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is… Expand
Is this relevant?
2016
2016
 
Is this relevant?